Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis

JP. Pelletier, JP. Raynauld, M. Dorais, L. Bessette, E. Dokoupilova, F. Morin, K. Pavelka, P. Paiement, J. Martel-Pelletier, DISSCO Trial Investigator Group

. 2020 ; 59 (12) : 3858-3868. [pub] 20201201

Jazyk angličtina Země Velká Británie

Typ dokumentu hodnocení ekvivalence, časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21011817

OBJECTIVE: The objective of this study was to investigate whether diacerein has comparable efficacy with celecoxib in pain reduction for treatment in symptomatic knee OA patients. METHODS: This randomized double-blind multicentre non-inferiority trial evaluated diacerein vs celecoxib treatment in patients with Kellgren-Lawrence grade 2-3 and pain scoring ≥4 (10-cm VAS). Patients were randomized to 6 months of treatment with diacerein 50 mg (n = 187) once daily for 1 month and twice daily thereafter, or celecoxib 200 mg (n = 193) once daily. The primary outcome was the change in WOMAC pain score (0-50 cm) at 6 months, and the secondary outcomes were WOMAC sub-scores, VAS pain score, and the OMERACT-OARSI responder rate. RESULTS: In the per protocol population, the adjusted mean change from baseline in the WOMAC pain score was -11.1 ( 0.9) with diacerein (n = 140) and -11.8 (0.9) with celecoxib (n = 148). The intergroup difference was 0.7 (95% CI: -1.8, 3.2; P = 0.597), meeting the non-inferiority margin. Supportive analysis of the intention-to-treat population gave similar results. Other outcomes showed no significant difference between treatment groups. The incidence of treatment-related adverse events was low and balanced between groups, but a greater incidence of diarrhoea occurred with diacerein (10.2% vs 3.7%). Diarrhoea was considered mild-to-moderate in all but one case with complete resolution. CONCLUSIONS: Diacerein was non-inferior to celecoxib in reducing knee OA pain and improving physical function. Diacerein also demonstrated a good safety profile. TRIAL REGISTRATION: A multicentre study on the effect of DIacerein on Structure and Symptoms vs Celecoxib in Osteoarthritis is a National Institutes of Health (NCT02688400) and European Clinical Trial Database (2015-002933-23) registered phase III (Canada) or IV (Europe) study.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21011817
003      
CZ-PrNML
005      
20210507104311.0
007      
ta
008      
210420s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/rheumatology/keaa072 $2 doi
035    __
$a (PubMed)32521015
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Pelletier, Jean-Pierre $u Osteoarthritis Research Unit, University of Montréal Hospital Research Centre (CRCHUM)
245    13
$a An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis / $c JP. Pelletier, JP. Raynauld, M. Dorais, L. Bessette, E. Dokoupilova, F. Morin, K. Pavelka, P. Paiement, J. Martel-Pelletier, DISSCO Trial Investigator Group
520    9_
$a OBJECTIVE: The objective of this study was to investigate whether diacerein has comparable efficacy with celecoxib in pain reduction for treatment in symptomatic knee OA patients. METHODS: This randomized double-blind multicentre non-inferiority trial evaluated diacerein vs celecoxib treatment in patients with Kellgren-Lawrence grade 2-3 and pain scoring ≥4 (10-cm VAS). Patients were randomized to 6 months of treatment with diacerein 50 mg (n = 187) once daily for 1 month and twice daily thereafter, or celecoxib 200 mg (n = 193) once daily. The primary outcome was the change in WOMAC pain score (0-50 cm) at 6 months, and the secondary outcomes were WOMAC sub-scores, VAS pain score, and the OMERACT-OARSI responder rate. RESULTS: In the per protocol population, the adjusted mean change from baseline in the WOMAC pain score was -11.1 ( 0.9) with diacerein (n = 140) and -11.8 (0.9) with celecoxib (n = 148). The intergroup difference was 0.7 (95% CI: -1.8, 3.2; P = 0.597), meeting the non-inferiority margin. Supportive analysis of the intention-to-treat population gave similar results. Other outcomes showed no significant difference between treatment groups. The incidence of treatment-related adverse events was low and balanced between groups, but a greater incidence of diarrhoea occurred with diacerein (10.2% vs 3.7%). Diarrhoea was considered mild-to-moderate in all but one case with complete resolution. CONCLUSIONS: Diacerein was non-inferior to celecoxib in reducing knee OA pain and improving physical function. Diacerein also demonstrated a good safety profile. TRIAL REGISTRATION: A multicentre study on the effect of DIacerein on Structure and Symptoms vs Celecoxib in Osteoarthritis is a National Institutes of Health (NCT02688400) and European Clinical Trial Database (2015-002933-23) registered phase III (Canada) or IV (Europe) study.
650    _2
$a anthrachinony $x terapeutické užití $7 D000880
650    _2
$a antiflogistika nesteroidní $x terapeutické užití $7 D000894
650    _2
$a artralgie $x farmakoterapie $7 D018771
650    _2
$a celekoxib $x terapeutické užití $7 D000068579
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a artróza kolenních kloubů $x farmakoterapie $7 D020370
650    _2
$a měření bolesti $7 D010147
655    _2
$a hodnocení ekvivalence $7 D000073843
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Raynauld, Jean-Pierre $u Institut de Rhumatologie de Montréal, Montréal, Québec
700    1_
$a Dorais, Marc $u StatSciences Inc., Notre-Dame-de-l'Île-Perrot
700    1_
$a Bessette, Louis $u Groupe de Recherche en Rhumatologie et Maladies Osseuses, Sainte-Foy, Québec, Canada
700    1_
$a Dokoupilova, Eva $u MEDICAL PLUS s.r.o., Uherske Hradiste, Faculty of Pharmacy, Department of Pharmaceutics, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic
700    1_
$a Morin, Frédéric $u Centre de Recherche Musculosquelettique, Trois-Rivières, Québec, Canada
700    1_
$a Pavelka, Karel $u Institute of Rheumatology and Clinic of Rheumatology, Prague, Czech Republic
700    1_
$a Paiement, Patrice $u Imaging Research & Development, ArthroLab Inc, Montréal, Québec, Canada
700    1_
$a Martel-Pelletier, Johanne $u Osteoarthritis Research Unit, University of Montréal Hospital Research Centre (CRCHUM)
710    2_
$a DISSCO Trial Investigator Group
773    0_
$w MED00011379 $t Rheumatology (Oxford, England) $x 1462-0332 $g Roč. 59, č. 12 (2020), s. 3858-3868
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32521015 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507104310 $b ABA008
999    __
$a ok $b bmc $g 1650249 $s 1132196
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 59 $c 12 $d 3858-3868 $e 20201201 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace